Corbus Pharmaceuticals Announces Presentation of Three

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
112
Corbus Pharmaceuticals Announces Presentation of Three Abstracts at the 2017 North American Cystic Fibrosis Conference

NORWOOD, MA --(Marketwired - September 25, 2017) - Corbus Pharmaceuticals Holdings, Inc. ( NASDAQ : CRBP ) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it will present three abstracts from its cystic fibrosis ("CF") research and clinical development programs at the 2017 North American Cystic Fibrosis Conference ("NACFC") being held November 2-4, in Indianapolis, IN.

James Chmiel, M.D., M.P.H., Professor of Pediatrics, Case Western Reserve University, Associate Director of the LeRoy W. Matthews Cystic Fibrosis Center at University Hospitals Rainbow Babies and Children's Hospital in Cleveland, and Principle Investigator of Corbus' Phase 2 cystic fibrosis clinical study will give an oral presentation, " Recent Advances in Anti-inflammatory Treatment, " on Friday, November 3, 2017 at 11:35 AM. As part of his presentation, Dr. Chmiel will review some of the latest trials of CF therapies including both CFTR modulators and immunomodulatory therapy for CF. Dr. Chmiel will also discuss clinical data from Corbus' Phase 2 study of anabasum for the treatment of CF and other developments in the field.

Listed below are the Company's abstract titles that have been accepted for poster presentation at the NACFC:

Poster No. 104 : " Anabasum Reduces Excessive Inflammatory Responses in Cystic Fibrosis Patient-Derived Lung Macrophages;"

Poster No. 272 : " A Double-Blind, Placebo Controlled Phase 2 Study in Adults with Cystic Fibrosis of Anabasum, A Selective Cannabinoid Receptor Type 2 Agonist;" and

Poster No. 312 : " Anabasum Enhances Resolution of Bacterial-Induced Inflammation in Healthy Humans."

The NACFC abstracts are now available in the online edition of Pediatric Pulmonology .

About Cystic Fibrosis

Cystic fibrosis is a chronic, life-threatening, genetic disease caused by inheriting two dysfunctional CFTR genes that normally regulate salt and water movement across cells in the respiratory and digestive systems. CF affects approximately 30,000 patients in the U.S and 75,000 patients worldwide. People with CF have thick, sticky mucus that clogs their airways, with recurrent bacterial infections and chronic inflammation in their lungs. In the gastrointestinal tract, they also have mucus accumulation, bacterial overgrowth, and inflammation. The dysfunctional CFTR genes cause an exaggerated inflammatory response that compounds the damage from a coexisting infection in the lungs and gut. CF results in destruction of lung tissue, lung fibrosis, pancreatic insufficiency, CF-related diabetes, malabsorption, malnutrition, growth retardation, and liver disease, including cirrhosis. The harmful inflammation and accompanying fibrosis in CF damages multiple organs, impairs organ function, reduces health-related quality of life, and can lead to death.

About Anabasum

Anabasum is a synthetic oral endocannabinoid-mimetic drug that preferentially binds to the CB2 receptor expressed on activated immune cells and fibroblasts. CB2 activation triggers endogenous pathways that resolve inflammation and halt fibrosis. Preclinical and human clinical studies have shown anabasum to have a favorable safety, tolerability and pharmacokinetic profile. It has also demonstrated promising potency in preclinical models of inflammation and fibrosis. Anabasum is designed to trigger the production of "Specialized Pro-resolving Lipid Mediators" that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of multiple inflammatory mediators. Anabasum also is designed to have a direct effect on fibroblasts to halt tissue scarring. In effect, anabasum is believed to trigger endogenous pathways to turn "off" chronic inflammation and fibrotic processes, without causing immunosuppression.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Anabasum has generated positive data in Phase 2 studies in diffuse cutaneous systemic sclerosis and cystic fibrosis, respectively. The Company also expects to report data from its Phase 2 study of anabasum in skin predominant dermatomyositis in the fourth quarter of 2017. Additionally, anabasum is being evaluated in open-label extension studies in systemic sclerosis and skin-predominant dermatomyositis, and in a Phase 2 study in systemic lupus erythematosus expected to commence in the fourth quarter of 2017.

Corbus plans to commence a Phase 3 study of anabasum for the treatment of systemic sclerosis in the fourth quarter of 2017. The Company is also planning to initiate a Phase 2b study of anabasum for the treatment of cystic fibrosis in the fourth quarter of 2017.

For more information, please visit www.CorbusPharma.com and connect with the Company on Twitter , LinkedIn , Google+ and Facebook .

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contacts Jenene Thomas Jenene Thomas Communications, LLC Phone: (908) 938-1475 Email: jenene@jenenethomascommunications.com Media Contact Nic DiBella JPA Health Communications Phone: (617) 657-1307 Email: Nic@jpa.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 60

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading

Top 5 Most Recently Viewed Articles

T-Mobile's Starlink Satellite Service Beta is Now Open for Signup

Updated Category News Views 270

T-Mobile Introduces Registration for Starlink Beta Program T-Mobile US, Inc. (NASDAQ: TMUS) has recently opened registrations for its much-anticipated beta program for Starlink, a direct-to-cell satellite service aimed at enhancing connectivity. This service promises to bridge the gaps in network coverage across vast areas of the United States, specifically targeting dead...

Continue Reading
WAVJA's Innovative Energy System Set to Change Indoor Power

Updated Category News Views 342

WAVJA's Photon Energy System Overview The energy landscape is undergoing significant changes, and WAVJA is at the forefront with its groundbreaking Photon Energy System (PES). This U.S.-based innovation is not just about powering homes; it's revolutionizing how we think about renewable sources of energy. In a time where climate challenges are prevalent, PES transforms the...

Continue Reading
Kipling Unveils New Collections at Exclusive London Event

Updated Category News Views 333

Kipling Launches Exciting New Collection in London Recently, Kipling captivated the fashion world by hosting an innovative and exclusive event in London. This gathering celebrated the unveiling of their latest collection, G.rilla Girlz, and brought a nostalgic touch by showcasing some of the brand's most iconic designs. A Night to Remember at Village Underground The event...

Continue Reading
Transforming TV Experiences: Cerence Renews Voice Interaction with LG

Updated Category News Views 159

Enhancing LG TVs with Conversational AI In a significant leap towards improved user experience, Cerence Inc. (NASDAQ: CRNC) has partnered with LG Electronics Inc. to integrate advanced voice interaction technology into LG's global television lineup. This innovative collaboration harnesses Cerence’s cloud-based neural text-to-speech (TTS) technology, enriching the way...

Continue Reading
Exciting Prize Opportunities as Bybit Welcomes New Traders to WSOT

Updated Category News Views 40

Bybit Enhances Participation Incentives for WSOT 2024 Bybit, a leading cryptocurrency exchange, is thrilled to announce an enticing prize opportunity aimed at encouraging last-minute participants in the World Series of Trading (WSOT) 2024. This newly implemented initiative allows late entrants to access a dedicated prize pool of 100,000 USDT. This bonus pool is designed...

Continue Reading